Sorafenib in Advanced Melanoma: A Critical Role for Pharmacokinetics?

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2012.287
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2015English

A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+Melanoma

Journal of Immunology
AllergyImmunology
2016English

A Clinical Phase II Study of Sorafenib in Advanced Hepatocellular Carcinoma

Anaplastology
2012English

A New B-Raf Inhibitor Combo for Advanced Melanoma

Oncotarget
Oncology
2018English

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Sorafenib for Advanced Hepatocellular Carcinoma (HCC): Impact of Rationing in the United Kingdom.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients

Clinical Cancer Research
Cancer ResearchOncology
2004English

Sorafenib Alone Versus Sorafenib Combined With Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses

Radiology
Nuclear MedicineRadiologyImaging
2013English

Transcatheter Arterial Chemoembolization After Stopping Sorafenib Therapy for Advanced Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy